Kuros Biosciences Ltd (CSBTF)
7.10
-1.95
(-21.55%)
USD |
OTCM |
Apr 30, 16:00
Kuros Biosciences Debt to Equity Ratio: 0.00 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| June 30, 2020 | 0.0014 |
| December 31, 2019 | 0.00 |
| June 30, 2019 | 0.0058 |
| Date | Value |
|---|---|
| December 31, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| December 31, 2015 | 0.3539 |
| June 30, 2015 | 0.00 |
| December 31, 2014 | -1.434 |
| June 30, 2014 | -1.725 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.0058
Maximum
Jun 2019
0.0007
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | 0.00 |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 85.08M |
| Total Liabilities (Quarterly) | 17.56M |
| Shareholders Equity (Quarterly) | 67.52M |
| Current Ratio | 2.062 |